乳腺癌BRCA1、BRCA2基因突变及其临床应用

摘要/Abstract

摘要：乳腺癌的发生与遗传因素密切相关。研究表明，乳腺癌易感基因(BRCA)1、2在乳腺癌的发生、发展过程中具有重要作用，针对BRCA基因突变的研究对乳腺癌的预防、诊断及治疗具有重要意义。

栗辰,黄焰. 乳腺癌BRCA1、BRCA2基因突变及其临床应用[J]. 国际肿瘤学杂志, 2015, 42(2): 138-140.

Li Chen, Huang Yan. Advances of BRCA1, BRCA2 mutation and their clinical applications[J]. Journal of International Oncology, 2015, 42(2): 138-140.

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30. ［2］ Morris JR, Boutell C, Keppler M, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress［J］. Nature, 2009, 462(7275): 886-890. ［3］ De Siervi A, De Luca P, Byun JS, et al. Transcriptional autoregulation by BRCA1［J］. Cancer Res, 2010, 70(2): 532-542. ［4］ Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2［J］. Science, 2014, 343(6178): 1470-1475. ［5］ Wang F, Fang Q, Ge Z, et al. Common BRCA1 and BRCA2 mutations in breast cancer families: a metaanalysis from systematic review［J］.Mol Biol Rep, 2012, 39(3): 2109-2118. ［6］ Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection［J］. Nat Rev Cancer, 2012, 12(1): 68-78. ［7］ Konstantopoulou I, Tsitlaidou M, Fostira F, et al. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families［J］. Clin Genet, 2014, 85(1): 36-42. ［8］ Kwong A, Ng EK, Wong CL, et al. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis［J］. PLoS One, 2012, 7(9): e43994. ［9］ Rao NY, Hu Z, Yu JM, et al. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients［J］. Breast Cancer Res Treat, 2009, 116(3): 563-570. ［10］ Zhang J, Pei R, Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer［J］. Breast Cancer Res Treat, 2012, 132(2): 421-428. ［11］ Ou J, Wu T, Sijmons R, et al. Prevalence of BRCA1 and BRCA2 germline mutations in breast cancer women of multiple ethnic region in northwest China［J］. J Breast Cancer, 2013, 16(1): 50-54. ［12］ Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breastovarian cancer［J］. Cancer, 2009, 115(10): 2222-2233. ［13］ Anders CK, Zagar TM, Carey LA. The management of earlystage and metastatic triplenegative breast cancer: a review［J］. Hematol Oncol Clin North Am, 2013, 27(4): 737-749. ［14］ Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014［J］. J Natl Compr Canc Netw, 2014, 12(4): 542-590. ［15］ Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility［J］. J Clin Oncol, 2010, 28(5): 893-901. ［16］ Singh K, Lester J, Karlan B, et al. Impact of family history on choosing riskreducing surgery among BRCA mutation carriers［J］. Am J Obstet Gynecol, 2013, 208(4): 329.e1-6. ［17］ Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. ［J］. J Clin Oncol, 2013, 31(25): 3091-3099. ［18］ Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres［J］. J Med Genet, 2009, 46(4): 254-258. ［19］ Malone KE, Begg CB, Haile RW, et al. Populationbased study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2［J］. J Clin Oncol, 2010, 28(14): 2404-2410. ［20］ Recht A. Contralateral prophylactic mastectomy: caveat emptor［J］. J Clin Oncol, 2009, 27(9): 1347-1349. ［21］ Balmana J, Diez O, Rubio IT, et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines［J］. Ann Oncol, 2011, 22 Suppl 6: vi31-34. ［22］ Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1positive breast cancers after neoadjuvant chemotherapy［J］. J Clin Oncol, 2010, 28(3): 375-379. ［23］ Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review［J］. Oncologist, 2013, 18(8): 909-916. ［24］ Tutt A, Robson M, Garber JE, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer a proofofconcept trial［J］. Lancet, 2010, 376(9737): 235-244.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[3]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[7]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[10]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇.Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[11]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣.三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[14]	刘博翰, 黄俊星.溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.

乳腺癌BRCA1、BRCA2基因突变及其临床应用

Advances of BRCA1, BRCA2 mutation and their clinical applications

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价